@phreakv6, As always a great summary from your end. You have largely focused on the potential of WCK 5222. If we look at the recent news articles, they attribute the price rise to the completion of the Phase 3 study of WCK 4873 (Nafithromycin).
In Phase 3 study, three-day treatment with Nafithromycin resulted in clinical cure for 96.7 per cent of patients as against clinical cure rate of 94.5 per cent in Moxifloxacin arm.
The study also establishes that Nafithromycin represents the first ever macrolide in 30 years which has successfully completed clinical development for the indication of community-acquired bacterial pneumonia. The currently available macrolide antibiotics Azithromycin and Clarithromycin were approved in 1988 and 1991 respectively. Since then no new macrolide antibiotics have been approved despite pneumonia causing about 2.5 million deaths annually worldwide as per WHO.
Do you have any idea how WCK 5222 and WCK 4873 are different? Both seem to be targeting a similar segment of bacterial infections.
Also, if the company gets approval for WCK 4873, does it mean they can target the Azithromycin market? which is valued at 6.9 Billion $
| Subscribe To Our Free Newsletter |
